Walleye Capital
KRYS icon

Walleye Capital’s Krystal Biotech KRYS Stock Holding History

Walleye Capital’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$232K Buy
+900
New +$239K ﹤0.01% 3245
2025
Q1 		– Sell
-1,700
Closed -$266K – 4695
2024
Q4 		$266K Buy
1,700
+600
+55% +$106K ﹤0.01% 3529
2024
Q3 		$200K Sell
1,100
-2,200
-67% -$424K ﹤0.01% 4008
2024
Q2 		$606K Buy
+3,300
New +$554K ﹤0.01% 3340
2023
Q3 		– Sell
-2,100
Closed -$247K – 5119
2023
Q2 		$247K Sell
2,100
-4,800
-70% -$490K ﹤0.01% 2949
2023
Q1 		$552K Buy
+6,900
New +$542K 0.01% 1627
2022
Q4 		– Sell
-3,000
Closed -$209K – 3425
2022
Q3 		$209K Buy
+3,000
New +$217K ﹤0.01% 2080

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Walleye Capital's KRYS Position: Q1 2026 in Review

Walleye Capital opened a new position in Krystal Biotech (KRYS) in Q1 2026: 354 shares worth $91.4K. The stake represents ﹤0.01% of the portfolio and ranks #3701 among its holdings. This is a return to the name: Walleye Capital previously reported a position in KRYS as recently as Q3 2024.

Walleye Capital first reported a position in KRYS in Q3 2024 and has held it in 2 quarters since. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Walleye Capital held 354 shares of Krystal Biotech worth $91.4K as of Q1 2026.
  • Krystal Biotech was a new Walleye Capital position in Q1 2026.
  • Krystal Biotech made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #3701 holding.
  • Walleye Capital first reported a position in Krystal Biotech in Q3 2024 and has held it in 2 quarters since.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.